Overhaul Call For Outdated EU Innovation Incentives
Tying supplementary protection certificates to the price of a product and replacing data exclusivity with data compensation are just two suggestions from a new paper on how EU incentives for pharmaceutical innovation should be overhauled.
You may also be interested in...
The European Commission is to conduct an analysis of the impact of incentives such as data exclusivity, market exclusivity and patent term extensions on innovation, drug pricing, and access to medicines, including generics. The move was requested by member state health ministers who say they are concerned about cases of 'very high and unsustainable price levels' hindering patient access to effective and affordable medicines.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.